ArticleInternational journal of pharmaceutics: X2026
Determination of the optimal resistance in RS01 for robust aerosol performance of inhaled controlled-release budesonide powder for chronic obstructive inflammatory respiratory diseases patients.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive inflammatory respiratory diseases are among the most common non communicable respiratory diseases worldwide. Although inhaled corticosteroids are effective, inadequate inspiratory flow through an inhaler can still result in poor asthma and COPD control. The patient's inhalation pattern directly determines the Fine Particle Dose (FPD) delivered to the lungs. This study evaluates which internal resistance of the RS01 inhaler, (low, medium-low, medium, or medium-high resistance) provides the most consistent FPD, of controlled-release budesonide dry powder, across inspiratory profiles typical in asthmatic and COPD patients. Inspiratory profiles were defined by peak inspiratory flow rates (PIFR) from 30 to 100 L/min, inhaled volumes (Vi) from 1 to 5 L and times to inhale (Ti) from 1 to 5 s. They were generated using a Breath-Simulator (BRS300i) coupled to a Next Generation Impactor connected to Alberta Idealized Throat, for strong
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.